JP2016530495A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530495A5
JP2016530495A5 JP2016522572A JP2016522572A JP2016530495A5 JP 2016530495 A5 JP2016530495 A5 JP 2016530495A5 JP 2016522572 A JP2016522572 A JP 2016522572A JP 2016522572 A JP2016522572 A JP 2016522572A JP 2016530495 A5 JP2016530495 A5 JP 2016530495A5
Authority
JP
Japan
Prior art keywords
antibody
drug
il6r
individual
tracer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016522572A
Other languages
English (en)
Japanese (ja)
Other versions
JP6563910B2 (ja
JP2016530495A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/063891 external-priority patent/WO2015000865A1/en
Publication of JP2016530495A publication Critical patent/JP2016530495A/ja
Publication of JP2016530495A5 publication Critical patent/JP2016530495A5/ja
Application granted granted Critical
Publication of JP6563910B2 publication Critical patent/JP6563910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016522572A 2013-07-04 2014-07-01 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ Active JP6563910B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13175091 2013-07-04
EP13175091.1 2013-07-04
PCT/EP2014/063891 WO2015000865A1 (en) 2013-07-04 2014-07-01 Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019137030A Division JP6761085B2 (ja) 2013-07-04 2019-07-25 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ

Publications (3)

Publication Number Publication Date
JP2016530495A JP2016530495A (ja) 2016-09-29
JP2016530495A5 true JP2016530495A5 (enExample) 2017-06-08
JP6563910B2 JP6563910B2 (ja) 2019-08-21

Family

ID=48703341

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016522572A Active JP6563910B2 (ja) 2013-07-04 2014-07-01 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ
JP2019137030A Active JP6761085B2 (ja) 2013-07-04 2019-07-25 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019137030A Active JP6761085B2 (ja) 2013-07-04 2019-07-25 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ

Country Status (10)

Country Link
US (2) US10168326B2 (enExample)
EP (1) EP3017303B1 (enExample)
JP (2) JP6563910B2 (enExample)
KR (1) KR102248581B1 (enExample)
CN (1) CN105378480B (enExample)
BR (1) BR112015032960B1 (enExample)
CA (1) CA2913687C (enExample)
MX (1) MX363403B (enExample)
RU (1) RU2674996C2 (enExample)
WO (1) WO2015000865A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
EP4137816B1 (en) * 2014-02-11 2025-03-19 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
WO2017102786A1 (en) * 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag Three-step acid dissociation enzyme linked immunosorbent (tadelis) assay
JP7376361B2 (ja) * 2017-03-07 2023-11-08 エフ. ホフマン-ラ ロシュ アーゲー 免疫調節マクロライドのための安定な配合物
CN110997727B (zh) * 2017-08-08 2025-03-18 豪夫迈·罗氏有限公司 用于确定微型猪样品中抗药物抗体的方法
JP7161534B2 (ja) * 2017-11-29 2022-10-26 エフ.ホフマン-ラ ロシュ アーゲー 標的による干渉が抑制された抗薬物抗体アッセイ
BR112020022912A2 (pt) 2018-07-10 2021-02-23 Regeneron Pharmaceuticals, Inc. métodos para mitigar a interferência de alvo de fármaco em um imunoensaio de anticorpo antifármaco (ada)
EP3969907B1 (en) * 2019-05-13 2025-09-24 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
EP4085251B1 (en) * 2020-01-02 2024-07-31 F. Hoffmann-La Roche AG Method for determining the amount of a therapeutic antibody in the brain
CN113495141A (zh) * 2020-03-20 2021-10-12 迈克生物股份有限公司 2019新型冠状病毒IgM抗体检测试剂盒
JP7525762B2 (ja) * 2020-05-18 2024-07-31 ビオシオン インコーポレイテッド Il6rに結合する抗体及びその使用
KR102626197B1 (ko) * 2020-11-19 2024-01-18 바디텍메드(주) 항 약물 항체의 수준을 정확하게 정량화하는 방법
JP7062803B1 (ja) 2021-03-31 2022-05-06 積水メディカル株式会社 抗薬物抗体測定方法
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
AU2024216670A1 (en) * 2023-02-07 2025-07-31 F. Hoffmann-La Roche Ag Method for the detection of anti-aav particle antibodies
GB2643845A (en) * 2023-04-20 2026-03-04 Xentria Inc Methods for detecting an anti-drug antibody (ADA) against an anti-TNF alpha antibody
CN120761634B (zh) * 2025-09-02 2025-12-05 宁波熙宁检测技术有限公司 一种针对多特异性单克隆抗体药物的ada检测方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
DE68928994T2 (de) 1988-11-03 1999-12-16 Igen International, Inc. Elektrochemilumineszente testverfahren
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
KR0132666B1 (en) 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
SG42954A1 (en) 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5821121A (en) 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
JPH08508875A (ja) 1992-05-01 1996-09-24 帝人株式会社 蛋白分泌細胞の流加回分培養法
EP0567738A3 (en) 1992-05-01 1995-09-06 American Cyanamid Co Controlling perfusion rates in continuous bioreactor culture of animal cells
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
JPH07258252A (ja) 1994-03-16 1995-10-09 Meiji Seika Kaisha Ltd チアゾール化合物およびその塩
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP3630453B2 (ja) 1994-09-30 2005-03-16 中外製薬株式会社 Il−6レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
US6086874A (en) 1994-12-29 2000-07-11 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
US6261560B1 (en) 1995-02-13 2001-07-17 Chugai Seiyaku Kabushiki Kaisha Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
ES2334408T3 (es) 1995-10-23 2010-03-09 Zenyth Operations Pty Ltd Receptor de hematopoyetina y secuencias geneticas que lo codifican.
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
DK0923941T3 (da) 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
ATE383875T1 (de) 1998-03-17 2008-02-15 Chugai Pharmaceutical Co Ltd Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
US6537782B1 (en) 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
CA2341239C (en) 1998-08-24 2011-01-04 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient
US6284453B1 (en) 1999-09-29 2001-09-04 Steven Anthony Siano Method for controlling fermentation growth and metabolism
EP1298217A4 (en) 2000-07-05 2004-09-08 Mitsubishi Pharma Corp Process for the production of a glycoprotein
WO2002013859A1 (en) 2000-08-10 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Method of inhibiting antibody-containing solution from coagulating or becoming turbid
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DK1356073T3 (da) 2000-10-20 2010-04-06 Bioneer As Fermenteringsfremgangsmåde til fremstilling af heterologe genprodukter i mælkesyrebakterier
CN1308447C (zh) 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
AU1095202A (en) 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
WO2002036164A1 (en) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
ES2869895T3 (es) 2001-03-09 2021-10-26 Chugai Pharmaceutical Co Ltd Método de purificación de proteínas
WO2002076578A1 (en) 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
CA2480059C (en) 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
JP3822137B2 (ja) 2002-05-20 2006-09-13 中外製薬株式会社 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
CN100522989C (zh) 2002-09-11 2009-08-05 中外制药株式会社 纯化蛋白质的方法
WO2004041216A2 (en) 2002-11-05 2004-05-21 Mount Sinai School Of Medicine Of New York University ; Ptpn11 (shp-2) mutations and cancer
DE10255508A1 (de) 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
EP1607100A4 (en) 2003-02-24 2007-06-13 Chugai Pharmaceutical Co Ltd MEDICAMENT WITH AN INTERLEUKIN-6 ANTAGONIST FOR BACK-MARGIN INJURIES
WO2004096274A1 (ja) 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. 気道内投与剤
CA2519113C (en) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DE602004027905D1 (de) 2003-05-15 2010-08-12 Wyeth Llc Kontrollierte glukosezufuhr für tierzellkultur
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
MXPA06003768A (es) 2003-10-17 2006-06-23 Chugai Pharmaceutical Co Ltd Agente terapeutico para el mesotelioma.
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US9714410B2 (en) 2005-01-05 2017-07-25 Chugai Seiyaku Kabushiki Kaisha Cell culture method and utilization of the same
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
JP4902674B2 (ja) 2006-03-09 2012-03-21 エフ.ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ法
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
JP5330829B2 (ja) 2006-08-04 2013-10-30 憲弘 西本 関節リウマチ患者の治療予後予測方法
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
JP2010095445A (ja) 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Il−6アンタゴニストを有効成分とする炎症性筋疾患治療剤
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
EP2174667B1 (en) 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
BRPI0817482B8 (pt) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
PL2202307T5 (pl) 2007-10-15 2021-10-04 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania przeciwciała
AU2008337904B2 (en) 2007-12-15 2014-02-13 F. Hoffmann-La Roche Ag Distinguishing assay
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
DE102008005523A1 (de) 2008-01-23 2009-07-30 Robert Bosch Gmbh Kraftstoffinjektor
CA2717614A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
DE102008013899A1 (de) 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag Verfahren zur Herstellung rekombinanter Proteine bei konstantem Gehalt von pCO2 im Medium
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
WO2011154139A2 (en) 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
CN103889555B (zh) 2011-09-01 2018-10-26 中外制药株式会社 通过超滤制备包含高度浓缩的抗体的组合物的方法

Similar Documents

Publication Publication Date Title
RU2016101730A (ru) Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
Robak et al. The role of Bruton’s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions
Quiros-Roldan et al. The impact of immune system aging on infectious diseases
Lee et al. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial
Kotsiou et al. Calprotectin in lung diseases
Iriart et al. Pneumocystis pneumonia in solid-organ transplant recipients
Nista et al. Autoimmune pancreatitis: from pathogenesis to treatment
Benfaremo et al. Systemic sclerosis: from pathophysiology to novel therapeutic approaches
JP2017538671A5 (enExample)
Amelio et al. Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania
JP2015530971A5 (enExample)
Galateanu et al. Allergy in cancer care: antineoplastic therapy-induced hypersensitivity reactions
JP2010539162A5 (enExample)
JP2014530226A5 (enExample)
JP2018052979A5 (enExample)
JP2016169229A5 (enExample)
MX2016005686A (es) Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
JP2016539925A5 (enExample)
Bąchor et al. Selected β2-, β3-and β2, 3-amino acid heterocyclic derivatives and their biological perspective
CN106381288A (zh) 一种抗h3n2亚型犬流感病毒核蛋白单克隆抗体杂交瘤2d10及单克隆抗体
Raacke et al. Altered cytokine response of human brain endothelial cells after stimulation with malaria patient plasma
Jasińska-Stroschein et al. Searching for Old and new small-molecule protein kinase inhibitors as effective treatments in pulmonary hypertension—a systematic review
JP2017538786A5 (enExample)
Yokoyama et al. Connective tissue disease-associated pulmonary arterial hypertension: current therapeutic strategies and future prospects
Passariello et al. A novel human neutralizing mAb recognizes delta, gamma and omicron variants of SARS-CoV-2 and can be used in combination with sotrovimab